icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL 2017 - European Association for the
Study of the Liver
Amsterdam, The Netherlands. 2017
Back grey_arrow_rt.gif
Prevention of Liver-Related Complications With Elbasvir/Grazoprevir in Hepatitis C Infected Patients Who Are Receiving Opioid Agonist Therapy (OAT)
  Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Shelby Corman1; Yiling Jiang2; Heather Loryn Platt3;Chizoba Nwankwo3 1Pharmerit International, Bethesda, MD, USA; 2Merck, Sharp & Dohme Limited, Hoddesdon, Hertfordshire, UK; 3Merck & Co., Inc., Kenilworth, NJ, USA
C-EDGE CO-STAR: Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 12 Weeks in HCV-infected Persons Who Inject Drugs on Opioid Agonist Therapy.....http://www.natap.org/2016/EASL/EASL_107.htm